S&P 500   3,966.85 (+1.68%)
DOW   31,875.39 (+1.96%)
QQQ   291.87 (+1.11%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
S&P 500   3,966.85 (+1.68%)
DOW   31,875.39 (+1.96%)
QQQ   291.87 (+1.11%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
S&P 500   3,966.85 (+1.68%)
DOW   31,875.39 (+1.96%)
QQQ   291.87 (+1.11%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
S&P 500   3,966.85 (+1.68%)
DOW   31,875.39 (+1.96%)
QQQ   291.87 (+1.11%)
AAPL   142.33 (+3.45%)
MSFT   259.44 (+2.72%)
FB   194.68 (+0.59%)
GOOGL   2,224.58 (+2.13%)
AMZN   2,115.88 (-1.67%)
TSLA   662.10 (-0.27%)
NVDA   165.58 (-0.81%)
BABA   86.63 (-0.18%)
NIO   15.73 (-4.32%)
AMD   93.80 (+0.32%)
CGC   5.17 (-6.34%)
MU   69.22 (+0.46%)
T   20.84 (+2.16%)
GE   75.91 (+0.88%)
F   12.83 (+2.64%)
DIS   104.87 (+2.39%)
AMC   11.59 (-3.66%)
PFE   52.96 (+0.93%)
PYPL   81.10 (+0.70%)
NFLX   184.85 (-0.80%)
NASDAQ:ARAY

Accuray (ARAY) Stock Forecast, Price & News

$2.19
+0.02 (+0.92%)
(As of 05/23/2022 01:39 PM ET)
Add
Compare
Today's Range
$2.11
$2.22
50-Day Range
$2.09
$3.52
52-Week Range
$2.08
$5.93
Volume
49,111 shs
Average Volume
811,347 shs
Market Capitalization
$203.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.92
30 days | 90 days | 365 days | Advanced Chart
Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

Accuray logo

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Headlines

Accuray (NASDAQ:ARAY) Raised to Buy at StockNews.com
Accuray (NASDAQ:ARAY) Downgraded by TheStreet
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ARAY
CUSIP
00439710
Employees
995
Year Founded
1990

Sales & Book Value

Annual Sales
$396.29 million
Cash Flow
$0.12 per share
Book Value
$0.56 per share

Profitability

Net Income
$-6.31 million
Pretax Margin
-2.62%

Debt

Price-To-Earnings

Miscellaneous

Free Float
89,090,000
Market Cap
$203.24 million
Optionable
Optionable

Company Calendar

Last Earnings
4/27/2022
Today
5/23/2022
Fiscal Year End
6/30/2022
Next Earnings (Estimated)
8/10/2022

Social Links


MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

365th out of 1,416 stocks

Surgical & Medical Instruments Industry

47th out of 138 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Accuray (NASDAQ:ARAY) Frequently Asked Questions

Is Accuray a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Accuray stock.
View analyst ratings for Accuray
or view top-rated stocks.

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Accuray
.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its earnings results on Wednesday, April, 27th. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.05. The medical equipment provider had revenue of $96.17 million for the quarter, compared to analysts' expectations of $99.50 million. Accuray had a negative net margin of 3.01% and a negative trailing twelve-month return on equity of 5.68%.
View Accuray's earnings history
.

What price target have analysts set for ARAY?

1 analysts have issued 12-month price objectives for Accuray's stock. Their forecasts range from $7.50 to $7.50. On average, they expect Accuray's share price to reach $7.50 in the next year. This suggests a possible upside of 242.5% from the stock's current price.
View analysts' price targets for Accuray
or view top-rated stocks among Wall Street analysts.

Who are Accuray's key executives?
Accuray's management team includes the following people:
What is Joshua Levine's approval rating as Accuray's CEO?

78 employees have rated Accuray CEO Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among Accuray's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.35%), Archon Capital Management LLC (6.14%), Neuberger Berman Group LLC (5.21%), Vanguard Group Inc. (4.86%), State Street Corp (3.73%) and Heartland Advisors Inc. (3.65%). Company insiders that own Accuray stock include Brandon W Green, Byron C Scott, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends for Accuray
.

Which major investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Rice Hall James & Associates LLC, Neuberger Berman Group LLC, Russell Investments Group Ltd., State Board of Administration of Florida Retirement System, Renaissance Technologies LLC, UBS Group AG, and Assenagon Asset Management S.A.. Company insiders that have sold Accuray company stock in the last year include Brandon W Green, Jesse Chew, Joshua Levine, Michael Hoge, Patrick Spine, and Suzanne C Winter.
View insider buying and selling activity for Accuray
or view top insider-selling stocks.

Which major investors are buying Accuray stock?

ARAY stock was bought by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, JPMorgan Chase & Co., Royce & Associates LP, First Trust Advisors LP, North Star Investment Management Corp., Acadian Asset Management LLC, Panagora Asset Management Inc., and State Street Corp. Company insiders that have bought Accuray stock in the last two years include Byron C Scott, Joseph E Whitters, Joshua Levine, and Suzanne C Winter.
View insider buying and selling activity for Accuray
or or view top insider-buying stocks.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $2.19.

How much money does Accuray make?

Accuray has a market capitalization of $203.24 million and generates $396.29 million in revenue each year. The medical equipment provider earns $-6.31 million in net income (profit) each year or ($0.140010) on an earnings per share basis.

How many employees does Accuray have?

Accuray employs 995 workers across the globe.

Does Accuray have any subsidiaries?

The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.

When was Accuray founded?

Accuray was founded in 1990.

What is Accuray's official website?

The official website for Accuray is www.accuray.com.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at (408) 716-4600, via email at [email protected], or via fax at 408-716-4601.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.